Magdalena O. CilellaPh.D.
Overview
Dr. Magdalena Cilella focuses on patent law matters related to molecular/cell biology, pharmaceuticals and biotechnology. Specifically, Magda has assisted clients with preparation and prosecution of patent applications relating to variety of technologies, including diagnostics, proteins, pharmaceuticals and cosmeceuticals, cell-based assays, plants and medical devices.
Magda brings to the firm a strong research background including experiences in neurodegeneration and tauopathies, specializing in intransglutaminase-induced cross-linking in progressive supranuclear palsy and the effects of Echinacea (over-the-counter dietary supplement) on the human immune system.
Career & Education
- Loyola University Chicago
Teaching Fellow, 2000–2002
Principles of Pharmacology (graduate level course)
- Loyola University Chicago
- Augustana College, B.A., cum laude, Biology and Pre-Medicine, 1997
- Loyola University Chicago Stritch School of Medicine, Ph.D., Pharmacology and Experimental Therapeutics, 2002
- U.S. Patent and Trademark Office (USPTO)
Professional Activities and Memberships
- Society for Neuroscience
- American Society for Pharmacology and Experimental Therapeutics
- American Association for the Advancement of Science
- Intellectual Property Owners Association
- Polish
- Russian
Magdalena's Insights
Publication | 12.26.24
Efficiency v Flexibility – The Patent Prosecution Highway (PPH) Program’s Pros and Cons
The Patent Prosecution Highway (PPH) program is a collaborative initiative between the United States Patent and Trademark Office (USPTO) and several foreign patent offices, created to speed up the examination process. Through the PPH, a patent application initially filed with a participating patent office (Office of Earlier Examination, or OEE) can be expedited in another participating intellectual property office, provided it meets specific requirements. According to the USPTO, PPH leverages fast-track examination procedures already in place among participating patent offices to allow applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing.
Publication | 11.01.03
"Transglutaminase-Induced Cross-Linking of Tau Proteins in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol. 59(11), November 2000, pgs 983-9
Publication | 02.01.03
"Transglutaminase Enzyme Activity and Expression of Transglutaminase 1 are increased in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol,"62(2), February 2003, pgs 173-84
Recognition
- Loyola University Chicago, Chicago Chapter for Neuroscience Annual Scientific Meeting, Student Speaker Representative, 2001
- Arthur J. Schmitt Dissertation Fellowship for outstanding academic achievements and in recognition of the scholarly promise of the proposed dissertation research, 2000
- American Society for Pharmacology and Experimental Therapeutics, Great Lakes Chapter: Third Place Award (poster presentation), 2000
Magdalena's Insights
Publication | 12.26.24
Efficiency v Flexibility – The Patent Prosecution Highway (PPH) Program’s Pros and Cons
The Patent Prosecution Highway (PPH) program is a collaborative initiative between the United States Patent and Trademark Office (USPTO) and several foreign patent offices, created to speed up the examination process. Through the PPH, a patent application initially filed with a participating patent office (Office of Earlier Examination, or OEE) can be expedited in another participating intellectual property office, provided it meets specific requirements. According to the USPTO, PPH leverages fast-track examination procedures already in place among participating patent offices to allow applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing.
Publication | 11.01.03
"Transglutaminase-Induced Cross-Linking of Tau Proteins in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol. 59(11), November 2000, pgs 983-9
Publication | 02.01.03
"Transglutaminase Enzyme Activity and Expression of Transglutaminase 1 are increased in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol,"62(2), February 2003, pgs 173-84
Insights
Publication | 11.01.03
Publication | 02.01.03
"Transglutaminase-Induced Cross-Linking of Tau Proteins in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol. 59(11), November 2000, pgs 983-9
|11.01.03
"Transglutaminase Enzyme Activity and Expression of Transglutaminase 1 are increased in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol,"62(2), February 2003, pgs 173-84
|02.01.03
Magdalena's Insights
Publication | 12.26.24
Efficiency v Flexibility – The Patent Prosecution Highway (PPH) Program’s Pros and Cons
The Patent Prosecution Highway (PPH) program is a collaborative initiative between the United States Patent and Trademark Office (USPTO) and several foreign patent offices, created to speed up the examination process. Through the PPH, a patent application initially filed with a participating patent office (Office of Earlier Examination, or OEE) can be expedited in another participating intellectual property office, provided it meets specific requirements. According to the USPTO, PPH leverages fast-track examination procedures already in place among participating patent offices to allow applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing.
Publication | 11.01.03
"Transglutaminase-Induced Cross-Linking of Tau Proteins in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol. 59(11), November 2000, pgs 983-9
Publication | 02.01.03
"Transglutaminase Enzyme Activity and Expression of Transglutaminase 1 are increased in Progressive Supranuclear Palsy," co-author, J Neuropath Exp Neurol,"62(2), February 2003, pgs 173-84
